We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Amedisys, Inc. (“Amedisys” or the “Company”) (NASDAQ: AMED), in connection with the proposed merger of the Company with Option Care Health, Inc. (NASDAQ: OPCH) (“Option Care”).  Under the terms of the merger agreement, the Company’s shareholders will receive $101 cash for each share of Amedisys common stock owned.

Weiss Law is investigating whether (i) Amedisys’ board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $101 per share merger consideration adequately compensates Amedisys’ shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, at least one analyst set a price target for the Company of $115 per share, $14.00 above the merger price.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

‍